Insiders · ARVN

Briggs Morrison

Director at Arvinas, Inc. (ARVN)

Briggs Morrison has filed 46 insider reports with the SEC since February 2021, as director at Arvinas, Inc. (ARVN), director at CRISPR Therapeutics AG (CRSP) and director at Werewolf Therapeutics, Inc. (HOWL) and at 4 more companies. In the last 12 months Briggs Morrison bought $268K of stock on the open market. The latest filing, on June 26, 2026, reports grant or award at Arvinas, Inc. (ARVN).

Filings
46
Companies
7
Bought on market
$595K
Sold on market
$27.2M

Companies where Briggs Morrison is an insider

CompanyRoleShares heldBoughtSoldAvg buyPrice nowLast filing
Arvinas, Inc. logo
ARVN
Arvinas, Inc.
Director111,548$495K$2.77M$9.90$6.46-35%Jun 26, 2026
CRISPR Therapeutics AG logo
CRSP
CRISPR Therapeutics AG
Directorsince June 20255,209$39.10Jun 9, 2026
Werewolf Therapeutics, Inc. logo
HOWL
Werewolf Therapeutics, Inc.
Director$0.9466Jun 13, 2025
Carisma Therapeutics Inc. logo
CARM
Carisma Therapeutics Inc.
Directorsince March 202312,175Jun 27, 2024
Repare Therapeutics Inc. logo
RPTX
Repare Therapeutics Inc.
DirectorJun 20, 2024
Syndax Pharmaceuticals Inc logo
SNDX
Syndax Pharmaceuticals Inc
Director34,836$24.4M$8.72Feb 9, 2024
Codiak BioSciences, Inc. logo
CDAK
Codiak BioSciences, Inc.
Director4,761$100K$21.00Feb 17, 2021

Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record. Price now: the latest daily close, against the average buy price.

Every filing

Also sits on boards with

Officers and directors who share two or more companies with Briggs Morrison.

Compare Briggs Morrison with

Other insiders at the same companies

Questions about Briggs Morrison

What is Briggs Morrison's role at Arvinas, Inc.?
Briggs Morrison reports to the SEC as director at Arvinas, Inc. (ARVN), according to the latest filing on June 26, 2026. Briggs Morrison has also filed as director at CRISPR Therapeutics AG (CRSP), director at Werewolf Therapeutics, Inc. (HOWL), director at Carisma Therapeutics Inc. (CARM) and director at Repare Therapeutics Inc. (RPTX).
How many shares does Briggs Morrison own?
After the latest filing that states it, Briggs Morrison directly owned 111,548 shares of Arvinas, Inc. (ARVN), 5,209 shares of CRISPR Therapeutics AG (CRSP), 12,175 shares of Carisma Therapeutics Inc. (CARM), 34,836 shares of Syndax Pharmaceuticals Inc (SNDX) and 4,761 shares of Codiak BioSciences, Inc. (CDAK). Shares held through trusts, funds or family members are reported separately and are not counted here.
Has Briggs Morrison bought or sold stock recently?
The most recent open-market purchase was on March 6, 2026: bought 20,000 shares of Arvinas, Inc. (ARVN) for $268K at an average of $13.40. The most recent open-market sale was on August 9, 2023: sold 52,855 shares of Syndax Pharmaceuticals Inc (SNDX) for $965K at an average of $18.27.
How do I get alerts when Briggs Morrison files?
Follow Briggs Morrison on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.

From SEC Forms 3, 4, 5 and 144 filed by Briggs Morrison (SEC CIK 0001654430). Totals count each trade once, skipping amendments whose original is on file, from Feb 5, 2021 on. View on SEC EDGAR · Get this as JSON